The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML.

Venclexta (venetoclax) - Roche, AbbVie

NTX-301 - PinotBio, Aston Sci.

azacitidine - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42439804

Bing Z Carter; Edward Ayoub; Guillermo Garcia-Manero; Kunal Rai; Lauren B Ostermann; Michael Andreeff; Po Yee Mak; Steffen Boettcher; Suresh Satpati; Torsten Haferlach; Yue Wei

Jul 14, 2026